<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33121553</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1092-8529</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS spectrums</Title>
          <ISOAbbreviation>CNS Spectr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.</ArticleTitle>
        <Pagination>
          <StartPage>199</StartPage>
          <EndPage>207</EndPage>
          <MedlinePgn>199-207</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1017/S1092852920001984</ELocationID>
        <Abstract>
          <AbstractText>Attention-deficit/hyperactivity disorder (ADHD), the single most common neuropsychiatric disorder with cognitive and behavioral manifestations, often starts in childhood and usually persists into adolescence and adulthood. Rarely seen alone, ADHD is most commonly complicated by other neuropsychiatric disorders that must be factored into any intervention plan to optimally address ADHD symptoms. With more than 30 classical Schedule II (CII) stimulant preparations available for ADHD treatment, only three nonstimulants (atomoxetine and extended-release formulations of clonidine and guanfacine) have been approved by the United States Food and Drug Administration (FDA), all of which focus on modulating the noradrenergic system. Given the heterogeneity and complex nature of ADHD in most patients, research efforts are identifying nonstimulants which modulate pathways beyond the noradrenergic system. New ADHD medications in clinical development include monoamine reuptake inhibitors, monoamine receptor modulators, and multimodal agents that combine receptor agonist/antagonist activity (receptor modulation) and monoamine transporter inhibition. Each of these "pipeline" ADHD medications has a unique chemical structure and differs in its pharmacologic profile in terms of molecular targets and mechanisms. The clinical role for each of these agents will need to be explored with regard to their potential to address the heterogeneity of individuals struggling with ADHD and ADHD-associated comorbidities. This review profiles alternatives to Schedule II (CII) stimulants that are in clinical stages of development (Phase 2 or 3). Particular attention is given to viloxazine extended-release, which has completed Phase 3 studies in children and adolescents with ADHD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cutler</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Neuroscience Education Institute and Department of Psychiatry, SUNY Upstate Medical University, Sarasota, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mattingly</LastName>
            <ForeName>Gregory W</ForeName>
            <Initials>GW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO and Midwest Research Group, St. Charles, MO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jain</LastName>
            <ForeName>Rakesh</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Texas Tech Health Sciences Center School of Medicine - Permian Basin, Midland, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neal</LastName>
            <ForeName>Welton</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Affairs, Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>CNS Spectr</MedlineTA>
        <NlmUniqueID>9702877</NlmUniqueID>
        <ISSNLinking>1092-8529</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30OMY4G3MK</RegistryNumber>
          <NameOfSubstance UI="D016316">Guanfacine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>57WVB6I2W0</RegistryNumber>
          <NameOfSubstance UI="D000069445">Atomoxetine Hydrochloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MN3L5RMN02</RegistryNumber>
          <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069445" MajorTopicYN="N">Atomoxetine Hydrochloride</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003000" MajorTopicYN="N">Clonidine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016316" MajorTopicYN="N">Guanfacine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADHD</Keyword>
        <Keyword MajorTopicYN="Y">atomoxetine</Keyword>
        <Keyword MajorTopicYN="Y">clonidine</Keyword>
        <Keyword MajorTopicYN="Y">guanfacine</Keyword>
        <Keyword MajorTopicYN="Y">nonstimulants</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33121553</ArticleId>
        <ArticleId IdType="doi">10.1017/S1092852920001984</ArticleId>
        <ArticleId IdType="pii">S1092852920001984</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
